Antagen Biosciences Inc.

Canton, MA

UEI
HXD6EFH2ND57
CAGE
59GJ1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
780 Dedham St #800, Canton, MA 02021, USA
Founded
2008
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Award to antagen pharmaceuticals 75N93022C00020 National Institute of Allergy and Infectious Diseases (NIH) $300,000
The goal of the proposed project is to further develop antagen's novel protein nanoparticle-based expression and… 75N93022C00011 National Institute of Allergy and Infectious Diseases (NIH) $299,998
Sbir topic 081: adjuvant development for vaccines against infectious or immune-mediated diseases 75N93020C00042 National Institute of Allergy and Infectious Diseases (NIH) $600,000
The objective of this contract is to use immunogens (ENVS) combined with effective multivalent antigenic display on… 75N93019C00014 National Institute of Allergy and Infectious Diseases (NIH) $599,914
The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing… 75N93018C00017 National Institute of Allergy and Infectious Diseases (NIH) $599,997

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
Florida International University Technical objectives are: 1) Engineer and express 10 malaria and/or mosquito proteins by mammalian CHO cell expression system, and purify the recombinant… R01AI179943 $193,651
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. INTRODUCTION/BACKGROUND: Main objective of this collaboration is to develop Fc engineered vaccines or therapeutics against human infectious diseases using… N626451920002 $52,961
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. INTRODUCTION/BACKGROUND: Main objective of this collaboration isto develop fully human or chimeric IgA-IgG hybrid monoclonal antibodies (mAbs) against… N626451920002 $82,016

Similar vendors

Vendor Location Primary NAICS
Tendel Therapies Inc. UEI JA9BDUH73852 Kensington, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Inimmune Corp UEI EF8AMXMGG8W5 Missoula, MT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Soligenix, Inc. UEI GVD4XBVYD9J5 Princeton, NJ 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Idbiologics Inc. UEI JMM8XMM89MQ5 Nashville, TN 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Neovaxsyn Inc. UEI EHMTBALCKFE8 Ames, IA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, is a for-profit biotechnology company focused on developing biologics to address unmet medical needs in infectious diseases, cancer, and autoimmune diseases. Through federal contract awards, Antagen provides research and development services related to novel vaccines, adjuvants, drug delivery systems, and other biomedical countermeasures.

Specific federal contracts awarded to Antagen include a $300,000 Phase I SBIR award from the National Institute of Allergy and Infectious Diseases to develop an engineered HIV envelope glycoprotein fused to Antagen's FcRider platform, intended to induce broadly neutralizing antibodies against HIV. Antagen also received a $600,000 SBIR award from NIAID to develop novel adjuvants to enhance vaccine efficacy against infectious and immune-mediated diseases. Additional prior awards include $299,998 under the SBIR program to further develop Antagen's nanoparticle-based vaccine delivery platform for inducing durable antibody responses, and $599,914 to use multivalent HIV envelope immunogens delivered on nanoparticles to promote somatic hypermutation toward broadly neutralizing HIV antibodies. All of Antagen's federal awards have been set aside for total small business participation.

SBA capabilities narrative

From the vendor's SBA profile

Platform for biotechnology transformation; biologics manufacturing, biologics supplies; high-throughput drug screening; protein expression system.

Quick answers

Is Antagen Biosciences Inc. registered in SAM.gov?

Yes. Antagen Biosciences Inc.'s SAM.gov registration is active through February 8, 2027.

What is Antagen Biosciences Inc.'s CAGE code?

Antagen Biosciences Inc.'s CAGE code is 59GJ1, and its Unique Entity ID (UEI) is HXD6EFH2ND57.

What is Antagen Biosciences Inc.'s most recent federal award?

Antagen Biosciences Inc.'s most recent federal contract award is Award to antagen pharmaceuticals (75N93022C00020), from National Institute of Allergy and Infectious Diseases (NIH), on July 5, 2022.

On GovTribe

See Antagen Biosciences Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe